OncoMatch/Clinical Trials/NCT05378425
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Is NCT05378425 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including NTX-1088 and Pembrolizumab for cancer.
Treatment: NTX-1088 · Pembrolizumab — This is a Phase 1,open-label, multi-center, first-in-human, 2-part (Part 1: dose escalation and Part 2: expansion) study, evaluating multiple doses and schedules of intravenously (IV) administered NTX-1088, with or without pembrolizumab, in patients with advanced solid malignancies (i.e., locally advanced or metastatic).
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: PVR overexpression
advanced (locally advanced or metastatic) malignant solid cancer known to express PVR
Disease stage
Metastatic disease required
advanced (locally advanced or metastatic) malignant solid cancer known to express PVR
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational agent targeting pvr
Lab requirements
Blood counts
ANC ≥1.5×10^9/L. Hemoglobin ≥9 g/dL and no red blood cell transfusions during the prior 14 days. Platelet count ≥100×10^9/L and no platelet transfusions during the prior 14 days.
Kidney function
CrCL ≥30 mL/min as calculated by the Cockcroft-Gault formula
Liver function
Bilirubin ≤1.5×ULN. AST and ALT ≤2.5×ULN. Patients may have ALT and AST <5×ULN if the patient has hepatic metastases.
Cardiac function
LVEF ≥45% as determined by ECHO or MUGA
adequate baseline organ function, as demonstrated by: CrCL ≥30 mL/min... Bilirubin ≤1.5×ULN. AST and ALT ≤2.5×ULN... Corrected calcium <11g/dL, Albumin >3g/dL... adequate baseline hematologic function... LVEF ≥45% as determined by either echocardiography (ECHO) or multigated acquisition (MUGA) scanning.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Ochsner Clinic Foundation · New Orleans, Louisiana
- The University of Texas MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify